The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.
Upon successful completion of this education activity, participants should be better able to:
Dana-Farber Cancer Institute
Harvard Medical School
Featured RMEI CE Activities